Table 1 Baseline descriptive characteristics of the study population.

From: Additive effects of coexisting respiratory comorbidities on overall or respiratory mortality in patients with asthma: a national cohort study

Ā 

Total

(n = 96,595)

Asthma cohorta

(n = 19,319)

Control cohort

(n = 77,276)

p-value

Age, years

49 (36–64)

49 (36–64)

49 (36–64)

Ā 

Age group

Ā Ā Ā 

 > 0.99

Twenties

11,880 (12.3)

2376 (12.3)

9504 (12.3)

Ā 

Thirties

19,255 (19.9)

3851 (19.9)

15,404 (19.9)

Ā 

Forties

18,370 (19.0)

3674 (19.0)

14,696 (19.0)

Ā 

Fifties

15,750 (16.3)

3150 (16.3)

12,600 (16.3)

Ā 

Sixties

16,610 (17.2)

3322 (17.2)

13,288 (17.2)

Ā 

Seventies

14,730 (15.3)

2946 (15.3)

11,784 (15.3)

Ā 

Sex

Ā Ā Ā 

 > 0.99

Male

34,720 (35.9)

6944 (35.9)

27,776 (35.9)

Ā 

Female

61,875 (64.1)

12,375 (64.1)

49,500 (64.1)

Ā 

Type of insurance

Ā Ā Ā 

 < 0.01

Self-employed health insurance

39,519 (40.9)

7369 (38.1)

32,150 (41.6)

Ā 

Employee health insurance

52,047 (53.9)

10,198 (52.8)

41,849 (54.2)

Ā 

Medical aid

5029 (5.2)

1752 (9.1)

3277 (4.2)

Ā 
  1. Data are presented as frequency (%) and mean with standard deviation.
  2. COPD, chronic obstructive pulmonary disease.
  3. aAsthma-related medication included inhaled corticosteroid (32%), long-acting β2 agonist (19.1%), short-acting β2 agonist (34.8%), and leukotriene receptor antagonist (35.7%).